Results 51 to 60 of about 382,920 (355)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi +5 more
wiley +1 more source
Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies
Advanced Healthcare Materials, EarlyView.Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best +5 more
wiley +1 more source
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
New England Journal of Medicine, 2019 BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA ...
A. Chari +51 more
semanticscholar +1 more source
Advanced Healthcare Materials, EarlyView.Microgel‐based 3D printed constructs represent a compelling and versatile innovation for engineering architecturally complex, dynamically remodelable, and biocompatible structures with high structural fidelity and bioactivity. By integrating material design, biofabrication, and biological function, these systems enable the development of adaptive ...
Elena Ghighină +2 more
wiley +1 more source
The Lancet Oncology, 2021 In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease.
E. Terpos +18 more
semanticscholar +1 more source
Blood Cancer JournalTeclistamab, a bispecific T-cell engager targeting BCMA and CD3, has demonstrated efficacy in relapsed/refractory multiple myeloma but may increase infection risk due to immunosuppression.
Hira Cheema +13 more
doaj +1 more source
Haematologica, 2020 The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not been explored.
Paolo Strati +15 more
doaj +1 more source
QJM, 1999 Survival for myeloma has improved from a median of 7 months in the 1950s to about 30 months today. Progress in chemotherapy has contributed a great deal to this improvement, although it may also, in part, reflect the improved treatment of infections, renal failure and hypercalcaemia as well as earlier diagnosis.
M L, Smith, A C, Newland
openaire +2 more sources
β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma
Advanced Science, EarlyView.β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto +20 more
wiley +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source